Helix BioPharma Corp. Reports Voting Results

RICHMOND HILL, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the Meeting.

There were 20 shareholders represented in person or by proxy at the Meeting holding 83,464,785 common shares, representing approximately 66.80% of Helix’s total issued and outstanding shares.

1.           Election of Directors

Each of the nominees for election as directors listed in Helix’s management information circular dated October 24, 2019 was elected as a director of Helix for the ensuing year or until their successors are elected or appointed. Management received proxies in respect of the election of directors of Helix as follows:

	Votes For		Votes Withheld
	#	%	#	%
Heman Chao	83,453,442	100.00	1,810	0.00
Ireneusz Fąfara	83,454,242	100.00	1,010	0.00
Artur Gabor	83,454,242	100.00	1,010	0.00
Slawomir Majewski	83,454,242	100.00	1,010	0.00

2.           Appointment of Auditor

BDO Canada LLP, Chartered Professional Accountants, was appointed auditor of Helix until the next annual meeting of shareholders at remuneration to be fixed by the directors. Management received proxies in respect of the appointment of the auditor of Helix as follows:

Votes For		Votes Withheld
#	%	#	%
83,452,773	99.99	12,010	0.01

3.           Equity Compensation Plan

The resolution approving all unallocated options, rights and other entitlements under Helix’s equity compensation plan; ratifying, confirming and approving such plan; and approving the granting by Helix of options, rights and other entitlements under such plan for a further three years until December 6, 2022 were approved by a majority of votes cast by shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Management received proxies in respect of the foregoing ratification, confirmation and approval with respect to the equity compensation plan as follows: